Hepatitis B virus reactivation in breast cancer patients undergoing chemotherapy: A review and meta‐analysis of prophylaxis management

摘要

Summary Hepatitis B virus ( HBV ) reactivation during or after chemotherapy in patients with breast cancer has become a remarkable clinical problem. Prophylactic nucleos(t)ide analogues ( NA s) are recommended for patients with breast cancer who are hepatitis B surface antigen ( HB sAg) positive before chemotherapy. We performed an up‐to‐date meta‐analysis to compare the efficacy of prophylactic lamivudine use with nonprophylaxis in HB sAg‐positive breast cancer patients undergoing chemotherapy. PubMed, the Cochrane Library and China National Knowledge Infrastructure ( CNKI ) databases were searched for relevant articles until June 2016. Eligible articles comparing the efficacy of prophylactic lamivudine use with nonprophylaxis in HB sAg‐positive breast cancer patients undergoing chemotherapy were identified. Eight studies which had enrolled 709 HB sAg‐positive breast cancer patients undergoing chemotherapy were analysed. Lamivudine prophylaxis significantly reduced the rates of chemotherapy‐associated hepatitis B flares in chronic hepatitis B in breast cancer compared with patients with nonprophylaxis (odds ratio [ OR ]=0.15, 95% confidence interval [ CI ]: 0.07‐0.35, P .00001). Chemotherapy disruption rates attributed to HBV reactivation in the prophylaxis groups were significantly lower than the nonprophylaxis groups ( OR =0.17, 95% CI : 0.07‐0.43, P =.0002). Patients with lamivudine prophylaxis had a higher risk for tyrosine‐methionine‐aspartate‐aspartate ( YMDD ) motif mutations than patients with nonprophylaxis ( OR =6.33, 95% CI : 1.01‐39.60, P =.05). Prophylactic antiviral therapy management is necessary for HB sAg‐positive breast cancer patients undergoing chemotherapy, in spite of high correlation with lamivudine‐resistant HBV variants with YMDD motif mutations.